PDX Pharmaceuticals in partnership with OHSU was among the four teams in Oregon that were awarded the 2022 Innovation in Philanthropy Award. The award recognizes PDX Pharma’s commitment (through donation and volunteer work at the BME of OHSU) in education and training in cancer research and nanotechnology. PDX Pharmaceuticals was also ranked among Oregon’s top ten […]
PDX Pharma is proud to be among seven companies that won a matching grant for phase II small business innovative research (SBIR) from Oregon State Lottery funds administered by Oregon Business Development Department. The award will be used for our IP protection, financing a new facility, and fundraising activities.
To read more, click here
Data on the ARAC (Antigen Release Agent and Checkpoint Inhibitor) technology has been published in Nature Communications (impact factor 17.7). ARAC is built upon our patented nanoparticle platform capable of co-delivering multiple therapeutic agents, while keeping a small size – similar to the size of a virus – suitable for infusion and tumor accumulation. ARAC co-delivers a polo-like kinase 1 (PLK1) inhibitor and a […]
PDX Pharmaceuticals, in collaboration with the Biomedical Engineering Department of Oregon Health and Science University, co-authored a cover article published in Small Journal, which describes our nano-therapeutic for treating advanced HER2+ breast cancer.
The article describes how our nanoparticle platform (Pdx-NP™) can load 3 different classes of therapeutics, including HER2 siRNA, docetaxel (chemotherapeutic) and trastuzumab […]
To date, we have had a total of 38 patent applications, and 3 patents were issued in the past 3 months. All thanks to our dedicated team of researchers.
-Patent No. 11,235,058, Immunotherapeutic constructs and methods of their use, February 1, 2022
Our article on in situ tumor vaccination with AIRISE-02 has been featured in Women in Materials Science collection, which celebrates excellence in the Advanced Materials family (Advanced Materials, Advanced Functional Materials, Advanced Science, and Small).
The Advanced Materials Family “support the most dedicated and enthusiastic scientists in the materials science disciplines in […]
PDX Pharmaceuticals, in collaboration with OHSU, has received a perfect score on its fast track SBIR grant application to the NCI. The application focuses on development of ARAC™ pipeline. Grant title: Novel Nano-immunotherapy for Treatment of Non-small Cell Lung Cancer, requested budget of $2.26 M over 3 years.
Furthermore, the team scored very high (18) on […]
June 12, 2021 PDX Pharmaceuticals, in collaboration with the Knight Cancer Institute and the Biomedical Engineering Department of Oregon Health and Science University, co-authored a paper published in the Advanced Materials Journal, which describes our immuno-nanotherapeutic candidate, Augmenting Immune Response and Inhibiting Suppressive Environment of the tumors,
PDX Pharma has received the USPTO’s Notice of Allowance for the patent application US 15/429,971 on its core nanoparticle technology (Pdx-NP) encompassing “Compositions” and “Method of Use” claims. The patent should be issued shortly. The technology is a joint invention of PDX Pharma and OHSU. It was first reported as a cover article in […]
Dr. Wassana Yantasee, CEO, presented an invited talk at the
2021 OHSU Research Week as part of the “Startup Company Showcase”
event in which OHSU startup companies share their compelling stories on bringing
medical technologies to the clinic. PDX Pharma was one of four companies
invited to present.
PDX Pharma is grateful for the support of the BME Department
PDX Pharmaceuticals received a second round of Series A funding in the amount of $2 million from the Kuni Foundation.
See the press release here
PDX’s CEO and Founder, Wassana Yantasee, PhD commented: “My team and I are excited to embark on this next phase of our clinical development initiatives with the intention of […]
PDX Pharmaceuticals is proud to report that we have filed two international patent applications (PCT) on cancer immunotherapeutics and a provisional application on COVID-19 vaccine today. Protection of intellectual properties (IPs) is our top priority and we work with one of the best IP law firms, Clark+Elbing, Boston, for patent application preparation and prosecution.
Proud to present PDX Pharma’s new review article in collaboration with OHSU and University of Texas MD Anderson Cancer Center. “Augmenting the therapeutic window of radiotherapy: A perspective on molecularly targeted therapies and nanomaterials” published in Radiotherapy and Oncology.
Targeted therapies may augment the therapeutic window of radiotherapy, but toxicities from combining radiation and targeted […]
PDX Pharmaceuticals named Greg Goodwin to its Board of Directors, currently consisting of Drs. Wassana Yantasee and Joe Gray.
Goodwin, a prominent business and community leader, formerly served as the Chief Executive Officer of Kuni Automotive, a Vancouver-based network of fifteen automobile dealerships in five states, including Oregon, Washington, California, Colorado, and Kansas. Goodwin retired […]
PDX Pharmaceuticals was selected to give a company presentation on the topic of “Precision medicine and therapeutic vaccines for cancer” at the Biocom’s 10th Annual Global Life Science Partnering Conference in San Diego on February 26th, 2020. We are grateful to OHSU’s Collaborations and Entrepreneurship program for its support.
PDX Pharmaceuticals received the Series A funding from The Wayne D. Kuni & Joan E. Kuni Foundation, based in Vancouver. This will serve as a matching fund for the phase IIB SBIR award from the NIH (max of $4M) that PDX Pharma is eligible to apply as a phase II SBIR awardee.
PDX Pharmaceuticals’ […]
PDX Pharmaceuticals hosts a visit from delegates from the Japan Health Sciences Foundation, consisting of CEO and managers from biotech and pharma companies from Japan. We are excited that they traveled to Portland to learn about our drug delivery platform and therapeutic vaccine projects, which may result in future partnership and collaboration.
Drs. Ngamcherdtrakul and Yantasee recently published a
review article “siRNA therapeutics for breast
cancer: recent efforts in targeting metastasis, drug resistance, and immune
evasion” in Translational Research.
In this Review, we describe recent efforts in developing siRNA therapeutics for the treatment of cancer, with particular emphasis on breast cancer. Instead of conventionally targeting proliferation and apoptosis aspects of tumorigenesis, […]
Dr. Wassana Yantasee, President/CEO, serves on scientific review panels for the DOD and NIH in November of 2019; the DOD’s BCRP Clinical & Experimental Therapeutics and the NIH’s SBIR/STTR on Platform Delivery Technologies for Nucleic Acid Therapeutics
Proud to present PDX Pharma’s new research article in collaboration with OHSU. “PLK1 and EGFR targeted nanoparticle as a radiation sensitizer for non-small cell lung cancer.” published in Cancer Letters.
Lung cancer is by far the leading cause of cancer death in men and women. Herein we utilize our nanoparticle platform for co-delivery of well […]
Dr. Wassana Yantasee, President/CEO, chaired a session at the Nanotechnologies for Drug Delivery Systems section at the BIT’s 17th Annual Congress of International Drug Discovery Science and Technology-2019 (IDDST-2019) which was held in Kyoto International Conference Center on July 25-27, and gave a talk titled “A versatile nanoparticle platform for targeted delivery of siRNA, chemodrug, […]
In her capacity as an OHSU faculty, Dr. Yantasee, President/CEO, and colleagues have been awarded the 2019 Circle of Giving grant by the OHSU Center for Women’s Health Circle of Giving, for the development of new cancer vaccines for triple negative breast cancer (TNBC).
Dr. Yantasee will work with OHSU’s Amanda Lund, Ph.D. and […]
PDX Pharma welcomes a new Scientist, Dr. Moataz Reda. Dr. Reda recently graduated from Oregon Health and Science University with a doctorate degree in biomedical engineering. His dissertation thesis was on the development of novel nanoparticle based PLK1, EGFR, and PD-L1 targeted therapies for lung cancer. He is our top recruit and we are excited […]
PDX Pharma welcomes a new Research Assistant, Ruijie Wang. Rujie recently graduated from University of Minnesota-Twin Cities with Bachelor of Science degree in Chemistry and a Minor in Pharmacology (GPA 3.57). Her undergraduate research experience in Dr. Zhengqiang Wang’s group involved the design and synthesis of TDP2 inhibitors — innovative drugs for cancer treatment. She […]
PDX Pharma welcomes a new Research Assistant, Molly Herinckx. Molly recently graduated from Oregon State University with an Honors Bachelor of Science degree in Molecular Biology and Biochemistry, and Minors in Chemistry and Spanish (GPA 3.97). Her Honors College thesis project focused on engineering mutant strains of Streptomyces fungicidicus to analyze the effect of […]
Daniel Bejan joined PDX Pharmaceuticals in 2017 as a research assistant and has recently been accepted into OHSU’s graduate Program in Molecular and Cellular Biosciences (PMCB). Along with his acceptance to PMCB, Daniel was selected as an OHSU ARCS (Achievement Rewards for College Scientists) Foundation Scholar . ARCS is national non-profit women’s organization whose goal […]
Dr. Worapol Ngamcherdtrakul, a principal scientist of PDX Pharmaceuticals, gave a talk entitled “Versatile Nanoparticles For Delivery Of siRNAs, Cancer Drugs, And Vaccine Agents: Systemic And Topical Applications” on March 18th, 2019 at the 2nd Annual Formulation & Drug Delivery USA Congress in San Diego, CA.
-Our versatile mesoporous silica nanoparticle platform has been designed and […]
Data on mesoporous silica modified with 1,2-hydroxypyridinone (1,2-HOPO) for capturing gadolinium based contrast agents in vitro and in a chronic kidney disease rodent model have been recently published in Scientific Reports. The work was done in collaboration between PDX Pharmaceuticals, the Biomedical Engineering Department of Oregon Health and Science University, and the Pacific Northwest National […]
PDX Pharma welcomes a new Research Assistant, Husam Zaidan. Husam recently graduated from University of Oregon with a Major in Biochemistry and a Minor in Biology. His Honors College thesis project focused on the antioxidative effects of organic polysulfide H2S donors. He is our top pick among 120 applicants. We are excited to add him […]
PDX Pharma’s President/CEO, Dr. Wassana Yantasee, gave a talk on the “Development of a New Oral Drug for Treating Chronic Mercury Exposure” on September 8th, at the 2018 International Academy of Oral Medicine and Toxicology (IAOMT) Symposium, in Vermont.
Highlights from her talk include:
-Mesoporous silica functionalized with a dense thiol monolayer rug (SH-SAMMS) is much more […]
PDX Pharma’s President/CEO, Dr. Wassana Yantasee, will serve as chair for session IV of the 2018 Nanomedicine and Drug Delivery Symposium, hosted in Portland, Oregon (September 21-23). PDX Pharmaceuticals, in collaboration with Oregon Health and Science University’s biomedical engineering department, will present two posters at the conference:
Nanoparticle-mediated co-delivery of taxane and siRNA to mirror the first […]
PDX Pharma has met all the milestones of the phase I portion of our fast-track SBIR project “Nanoparticle-based targeted codelivery of siRNA and taxane to treat drug-resistant HER2+ breast cancer” and has been approved for starting the phase II portion of the project by the NCI. The project period is from 06/01/2018 to 05/31/2020.
PDX Pharma’s President/CEO, Dr. Wassana Yantasee, is currently serving as the guest editor in the special issue “Nanoparticles in Therapeutic Applications” for the MDPI Bioengineering journal. The special issue focuses on nanoparticle development and applications in broad ranges of diseases and delivery routes.
More information can be found here.
PDX Pharma’s President/CEO, Dr. Wassana Yantasee, has served as a reviewer for the ZRG1 IMST-L (55) PAR-17-240 ‘Innovative Research in Cancer Nanotechnology (IRCN)’ (R01) Study Section for the National Institute of Health (NIH), held in Washington DC on March 29, 2018.
PDX Pharmaceuticals, in collaboration with the Biomedical Engineering Department of Oregon Health and Science University, has developed PDX-001 as a targeted nanoparticle for delivery of therapeutic siRNA for treating HER2+ breast cancer. The work has been funded by fast-track phase I/II SBIR awards from the NIH/NCI as well as angel funds (the Prospect Creek Foundation […]
PDX-001 is a targeted nanoparticle for delivery of therapeutic siRNA for treating HER2+ and triple-negative breast cancer. The development is a collaborative work between PDX Pharma and the Biomedical Engineering Department of OHSU. The work has been funded by fast-track phase I/II SBIR awards from NIH/NCI, a phase I SBIR award from NIH/NCATS, and angel […]
PDX Pharmaceuticals, Inc. has been selected to participate as a member of the 2017-2018 Cohort of the NIH SBIR/STTR Commercialization Accelerator Program (CAP) for Phase II awardees. “NIH CAP is a 9-month program that is well-regarded for its combination of deep domain expertise and access to industry connections, which have resulted […]
PDX Pharma’s President has served as a reviewer for the BST-F (80) Bioengineering ‘Academic Research Enhancement Award’ Study Section for the National Institute of Health (NIH) held on September 14, 2017.
PDX Pharma welcomes a new Research Assistant, Daniel Bejan. Daniel’s recently graduated from WSU Vancouver with a Major in Biology and Minors in Chemistry and Molecular Biology (GPA 3.94). He is our top pick among 120 applicants. We are excited to add him to our team.
Today, PDX Pharmaceuticals, in collaboration with the Biomedical Engineering Department of Oregon Health and Science University, was awarded a phase I SBIR grant from the National Center for Advancing Translational Sciences to support our pre-clinical research activity during the period of Aug 2017 – Aug 2018. The grant is entitled “Development of topical formulation of […]
PDX Pharma’s President has served as a reviewer for the ZRG1 BST-H (50) PAR-16-390 ‘NIBIB Trailblazer Award for New and Early Stage Investigators’ (R21) Study Section for the National Institute of Health (NIH) held on June 28, 2017.
Today, PDX Pharmaceuticals, in collaboration with the Biomedical Engineering Department of Oregon Health and Science University, was awarded a phase I/II (Fast-Track) SBIR grant from the National Cancer Institute to support our pre-clinical research activity during the period of May 2017 – May 2020. The grant is entitled “Nanoparticle-based targeted co-delivery of siRNA and taxane […]
PDX Pharma’s President has served as a reviewer for the BST-F (80) Bioengineering ‘Academic Research Enhancement Award’ Study Section for the National Institute of Health (NIH) held on March 9, 2017.
PDX Pharma’s President has served as a reviewer for the Fellowship: Cell Biology, Developmental Biology, and Bioengineering [F05] Study Section for the National Institute of Health (NIH) held on February 28, 2017 – March 1, 2017.
PDX Pharmaceuticals has published recent data on PDX-001 in collaboration with the Biomedical Engineering Department of Oregon Health and Science University. PDX-001 is a targeted nanoparticle for delivery of therapeutic siRNA for treating HER2+ and triple-negative breast cancer. The development is in collaboration with OHSU. It has been funded by a fast-track phase I/II SBIR […]
PDX Pharmaceuticals has published recent data on PDX-001 in collaboration with the Biomedical Engineering Department of Oregon Health and Science University. PDX-001 is a targeted nanoparticle for delivery of therapeutic siRNA for treating HER2+ breast cancer. The development is in collaboration with OHSU. It has been funded by a fast-track phase I/II SBIR contract from […]
PDX Pharma’s President will chair a Nanomedicine/Health Systems section of the 4th Sustainable Nanotechnology Organization Conference, to be held on November 8-10th in Portland, OR.
PDX Pharma’s President has served as a reviewer for the Gene and Drug Delivery Study Section for the National Institute of Heath (NIH) held in San Francisco from October 21-22th, 2015
PDX Pharmaceuticals has published recent data on PDX-002 in collaboration with the Biomedical Engineering Department of Oregon Health and Science University . PDX-002 is a nanoparticle platform for siRNA delivery designed to treat fibrosis, a complex disease characterized by increased oxidative stress, inflammation, and an excessive accumulation of extracellular matrices mainly consisting of collagen. Notably, […]
Development of antioxidant nanoparticle platform for delivery of siRNA and chemodrugs, Department of Chemistry Seminar Series, Portland State University, May 18th, 2018
Development of a Targeted Therapeutic and Radiation Sensitizer for Lung Cancer, 63rd annual Radiation Research Society (RRS) meeting, Cancun, MX, October 15th, 2017
siRNA-nanoparticles for treating drug-resistant breast cancer, Gordon RNA Technology, Ventura, CA, Feb 1-6. 2015
New methodologies for cancer target identification, personalized medicine in cancer care, and novel therapies based on nanomedicine, BDMS Meeting, Bangkok, Thailand, December 26, 2014 (invited).
OHSU’s effort to understand complex biological systems of cancer leading to targeted therapy with siRNA-nanoparticles, Siriraj School of Medicine, Bangkok, Thailand, December 22, 2014 (invited).
Bioreducible-crosslinked polymer coated mesoporous silica nanoparticles for siRNA targeted delivery to HER2+ breast cancer, 4th International Conference on Nanotek & Expo, San Francisco, CA, December 12, 2014 (invited).
Antibody-conjugated Nanoparticle Platform for Targeted Delivery of SiRNA to HER2+ Breast Cancer, BMES Annual Meeting 2014, San Antonio, TX, October 24, 2014.
SiRNA-mediated Targeting of HER2 as a Viable Approach for Treating Trastuzumab Resistant Breast Cancer, WIN Symposium 2014, Paris, France, June 23, 2014.
Development of a nanoparticle platform for the targeted delivery of siRNA to HER2-positive breast cancers, AACR Annual meeting 2014, San Diego, CA, April 9, 2014.
Nanoparticle Platform for siRNA Delivery with ROS Scavenging Properties for Treating Fibrosis, Keystone Symposium, Fibrosis: From Bench to Bedside (C4), Keystone, CO, March 24, 2014.
Development of a Nanoparticle platform for the Targeted Delivery of siRNA to HER2-positive Breast Cancers, 53rd Annual Meeting and ToxExpo, Society of Toxicology, Phoenix, AZ , March 25, 2014.
Novel Oral Detoxification of Mercury, Cadmium, and Lead with Thiol-Modified Mesoporous Silica, 53rd Annual Meeting and ToxExpo, Society of Toxicology, Phoenix, AZ, March 27, 2014.
Potential Use of Mesoporous Silica Nanoparticle for siRNA Delivery Agent and ROS Scavenger in Fibrotic Diseases, IEEE-Nanomed 2013, Phuket, Thailand, November 11, 2013.
Development of Lanthanide-loaded Mesoporous Silica Nanoparticles for Multi-parametric Single Cell Analysis by Mass Cytometry, IEEE-Nanomed 2013, Phuket, Thailand, November 12, 2013.
Nanoparticle platform for targeted delivery of siRNA and chemotherapies, (keynote presentation), IEEE-Nanomed 2013, Phuket, Thailand, November 12, 2013.
Nanoparticle platform for therapeutic siRNA delivery to HER2 positive breast cancer, TechConnect World 2012 – Nanotech, Santa Clara, CA, June, 2012.